Effectiveness and persistence of F/TAF-containing regimens (E/C/F/TAF, R/F/TAF or F/TAF+3rd agent) in late and very late presenters: final 24-month results from the German TAFNES cohort study

被引：0
|
作者：
Postel, N.
Jessen, H. [1 ]
Pauli, R. [2 ]
Hillenbrand, H. [3 ]
Heuchel, T. [4 ]
Rieke, A. [5 ]
Knechten, H. [6 ]
Emmerich, C. [7 ]
Schreiber, S. [7 ]
Mack, F. [7 ]
Haubrich, R. [8 ]
Stellbrink, H. [9 ]
机构：
[1] Praxis Jessen2 Kollegen, Clin Care, Berlin, Germany
[2] Gemeinschaftspraxis Becker Pauli, Clin Care, Munich, Germany
[3] MVZ Praxis City Ost, Clin Care, Berlin, Germany
[4] Praxis Heuchel, Clin Care, Chemnitz, Germany
[5] Gemeinschaftspraxis Koblenz Mayen Kemperhof, Clin Care, Koblenz, Germany
[6] PZB, Clin Care, Aachen, Germany
[7] Gilead Sci, Med Affairs, Munich, Germany
[8] Gilead Sci, Med Affairs, Foster City, CA USA
[9] ICH Study Ctr, Clin Care, Hamburg, Germany
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P129
引用
收藏
页码：108 / 109
页数：2
相关论文
共 20 条
  • [1] Effectiveness and persistence of E/C/F/TAF, R/F/TAF or F/TAF+3rd agent in late and very late presenters-final 24 month results from the German TAFNES cohort study
    Postel, Nils
    Jessen, Heiko
    Pauli, Ramona
    Hillenbrand, Heribert
    Rieke, Ansgar
    Knechten, Heribert
    Stellbrink, Hans-Juergen
    Emmerich, Claudia
    Schreiber, Sandra
    Mack, Frank
    Haubrich, Richard
    [J]. INFECTION, 2021, 49 (SUPPL 1) : S16 - S17
  • [2] 24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients
    Knechten, H.
    Schneeweiss, S.
    Schuebel, N.
    Hillenbrand, H.
    Kuemmerle, T.
    Schreiber, S.
    Goerner, K.
    Heinzkill, M.
    Haubrich, R.
    Stellbrink, H-J
    [J]. HIV MEDICINE, 2019, 20 : 60 - 61
  • [3] Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF in treatment-experienced HIV-1 infected patients: 12-month results from the German TAFNES cohort study
    Hillenbrand, H.
    Knechten, H.
    Kuemmerle, T.
    Scholten, S.
    Schuebel, N.
    Haubrich, R.
    Heinzkill, M.
    Goerner, K.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [4] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients-24-month results from the German TAFNES cohort study
    Pauli, R.
    Jessen, H.
    Postel, N.
    Heuchel, T.
    Rieke, A.
    Hillenbrand, H.
    Kuemmerle, T.
    Schreiber, S.
    Goerner, K.
    Heinzkill, M.
    Haubrich, R.
    Stellbrink, H-J
    [J]. HIV MEDICINE, 2019, 20 : 54 - 55
  • [5] Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF use in treatment-naive HIV-1 infected patients: 12-month results from the German TAFNES cohort study
    Heuchel, T.
    Hillenbrand, H.
    Jessen, H.
    Pauli, R.
    Postel, N.
    Haubrich, R.
    Heinzkill, M.
    Goerner, K.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [6] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study
    Stellbrink, H.
    Scholten, S.
    Hillenbrand, H.
    Knechten, H.
    Jessen, H.
    Schreiber, S.
    Goerner, K.
    Haubrich, R.
    Heinzkill, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 54 - 55
  • [7] Impact of baseline comorbidities on ART persistence and effectiveness in PLWH receiving F/TAF-based regimens: final 24-month results from the German TAFNES cohort study
    Scholten, S.
    Hillenbrand, H.
    Postel, N.
    Knechten, H.
    Pauli, R.
    Jessen, H.
    Emmerich, C.
    Pehlivan, C.
    Albuquerque, B.
    Haubrich, R.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 67 - 68
  • [8] Week 24 data from a Phase 3 clinical trial of E/C/F/TAF in HIV-infected adolescents
    Shao, Y.
    Bennett, S. R.
    Cheng, A.
    Quirk, E.
    Lawson, E.
    Gaur, A.
    Prasitsuebsai, W.
    Kizito, K.
    Whitehead, T.
    [J]. HIV MEDICINE, 2015, 16 : 15 - 15
  • [9] Real-world persistence of E/C/F/TAF versus DTG+ABC/3TC regimens for treatment of HIV in a large Spanish cohort: VACH
    Teira, R.
    Romero, A.
    Roca, B.
    Munoz-Sanchez, M.
    Sepulveda, M.
    Puig, T.
    Espinosa, N.
    Merino, M.
    Geijo, P.
    Castano, M.
    Estrada, V.
    Ribera, E.
    Domingo, P.
    De la Fuente, B.
    Montero, M.
    Galindo, M.
    Peraire, J.
    Martinez, E.
    Lozano, F.
    Terron, A.
    Garcia, J.
    Deig, E.
    Munoz-Sanz, A.
    Gutierrez, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [10] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late presentation in a multi-country cohort study
    Trottier, B.
    Antinori, A.
    De Wet, J.
    Duvivier, C.
    Elinav, H.
    Esser, S.
    Ghosn, J.
    den Hollander, J.
    Lambert, J.
    Milinkovic, A.
    Elliott, C.
    Saifi, T.
    Haubrich, R.
    Thorpe, D.
    Marongiu, A.
    Miralles, C.
    Schellberg, S.
    van Welzen, B.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 69 - 70
12